Affiliation:
1. Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
2. Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA
Abstract
Amid a reappraisal of the medicinal and societal worth of psychedelics in many countries, regulatory and financial barriers to conducting clinical research with these compounds appear to be receding. Still, there remains a strong need for a clearer understanding of naturalistic psychedelic use and its associated epidemiology, since this type of psychedelic use, which is growing in many places, will almost certainly always exceed clinical use. Furthermore, psychedelics behave differently depending on the settings in which they are used, meaning many research findings on their effects may significantly differ depending on the contexts in which they are observed. Therefore, improving the collection of data on real-world psychedelic use should be of higher priority for the public health community. Expanding data collection on psychedelic use in the United States National Survey on Drug Use and Health, an already vital tool for researchers examining naturalistic psychedelic use, could address this important public health need, helping ensure the general public, the scientific community, and regulators have access to high-quality information as peoples across the world reevaluate what psychedelics’ place in medicine and society should be.
Subject
Pharmacology (medical),Psychiatry and Mental health,Pharmacology
Reference23 articles.
1. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020
2. British Broadcasting Corporation (2022) Canada trials decriminalising cocaine, MDMA and other drugs. BBC News, 1 June. London: British Broadcasting Corporation. Available at: https://www.bbc.com/news/world-us-canada-61657095 (accessed 2 June 2022).
3. Campbell D (2022) Demand grows for UK ministers to reclassify psilocybin for medical research. The Guardian, 7 March. London: Guardian Media Group. Available at: https://www.theguardian.com/science/2022/mar/08/demand-grows-for-uk-ministers-to-reclassify-psilocybin-for-medical-research (accessed 2 June 2022).
4. Global Drug Survey (2022) Survey composition. Available at: https://www.globaldrugsurvey.com/gds-surveys/survey-composition/ (accessed 2 June 2022).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献